Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dysfunctional activity of classical DNA end-joining renders acquired resistance to carboplatin in human ovarian cancer cells
Authors
Keywords
Ovarian cancer, Chemoresistance, DNA damage Response, DNA repair, Non-homologous end joining
Journal
CANCER LETTERS
Volume 520, Issue -, Pages 267-280
Publisher
Elsevier BV
Online
2021-08-08
DOI
10.1016/j.canlet.2021.08.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Multidrug Resistance in Cancer Chemotherapy
- (2020) Karol Bukowski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mitochondria participate in chemoresistance to cisplatin in human ovarian cancer cells
- (2020) Luca X Zampieri et al. MOLECULAR CANCER RESEARCH
- Visualizing and interpreting cancer genomics data via the Xena platform
- (2020) Mary J. Goldman et al. NATURE BIOTECHNOLOGY
- Deficiency in classical nonhomologous end-joining–mediated repair of transcribed genes is linked to SCA3 pathogenesis
- (2020) Anirban Chakraborty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
- (2020) Sanghoon Lee et al. Cell Reports
- Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression
- (2019) Junli Deng et al. BMC CANCER
- Prosthesis design influences segmental contribution to total cervical motion after cervical disc arthroplasty
- (2019) Avinash G. Patwardhan et al. EUROPEAN SPINE JOURNAL
- Ovarian Cancer Immunotherapy: Turning up the Heat
- (2019) Eleonora Ghisoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Modulation of the Apoptosis Gene Bcl-x Function Through Alternative Splicing
- (2019) Megan Stevens et al. Frontiers in Genetics
- Regulation of DNA repair in the absence of classical non-homologous end joining
- (2018) Youn-Jung Kang et al. DNA REPAIR
- Homologous recombination and the repair of DNA double-strand breaks
- (2018) William Douglass Wright et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Chemoresistance and the Self-Maintaining Tumor Microenvironment
- (2018) Gulcen Yeldag et al. Cancers
- Nonhomologous DNA end-joining for repair of DNA double-strand breaks
- (2017) Nicholas R. Pannunzio et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BCL-XL overexpression promotes tumor progression-associated properties
- (2017) Daniela Trisciuoglio et al. Cell Death & Disease
- Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
- (2017) Jennifer Ducie et al. Nature Communications
- Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival
- (2017) Youn-Jung Kang et al. Nature Communications
- The molecular mechanisms of chemoresistance in cancers
- (2017) Hua-Chuan Zheng Oncotarget
- PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
- (2017) Tarra Evans et al. Therapeutic Advances in Medical Oncology
- Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future
- (2017) Emma C. Fields et al. Frontiers in Oncology
- Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells
- (2016) Carlos Cardenas et al. APOPTOSIS
- Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
- (2016) Aiste McCormick et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibition in ovarian cancer
- (2016) Junzo Hamanishi et al. INTERNATIONAL IMMUNOLOGY
- DNA Double-Strand Break Repair Inhibitors as Cancer Therapeutics
- (2015) Mrinal Srivastava et al. CHEMISTRY & BIOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Damage Response Factors from Diverse Pathways, Including DNA Crosslink Repair, Mediate Alternative End Joining
- (2015) Sean M. Howard et al. PLoS Genetics
- DNA repair mechanisms in cancer development and therapy
- (2015) Alessandro Torgovnick et al. Frontiers in Genetics
- MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer
- (2014) Zsófia Pénzváltó et al. BMC CANCER
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Novel role for non-homologous end joining in the formation of double minutes in methotrexate-resistant colon cancer cells
- (2014) Xiangning Meng et al. JOURNAL OF MEDICAL GENETICS
- Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
- (2014) Felix Dietlein et al. TRENDS IN GENETICS
- COSMIC (Cohort Studies of Memory in an International Consortium): An international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups
- (2013) Perminder S Sachdev et al. BMC Neurology
- Analysis on Outcome of 3537 Patients with Coronary Artery Disease: Integrative Medicine for Cardiovascular Events
- (2013) Zhu-ye Gao et al. Evidence-based Complementary and Alternative Medicine
- Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis
- (2013) Elena Lum et al. GYNECOLOGIC ONCOLOGY
- Signal Transduction Pathways and Transcriptional Mechanisms of ABCB1/Pgp-mediated Multiple Drug Resistance in Human Cancer Cells
- (2013) H Sui et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Optimal first-line treatment in ovarian cancer
- (2012) F. A. Raja et al. ANNALS OF ONCOLOGY
- New Insight into P-Glycoprotein as a Drug Target
- (2012) Albert Breier et al. Anti-Cancer Agents in Medicinal Chemistry
- Fast gapped-read alignment with Bowtie 2
- (2012) Ben Langmead et al. NATURE METHODS
- Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
- (2011) S. E. Polo et al. GENES & DEVELOPMENT
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- γH2AX: a sensitive molecular marker of DNA damage and repair
- (2010) L-J Mah et al. LEUKEMIA
- ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks
- (2009) Gabriela Bindea et al. BIOINFORMATICS
- DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells
- (2009) Florian T Unger et al. BMC CANCER
- MicroRNAs in ovarian carcinomas
- (2009) Neetu Dahiya et al. ENDOCRINE-RELATED CANCER
- Impaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy
- (2009) Zbigniew Darzynkiewicz et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- First-line treatment of advanced ovarian cancer: current research and perspectives
- (2009) Claudia Marchetti et al. Expert Review of Anticancer Therapy
- FAUregulates carboplatin resistance in ovarian cancer
- (2009) Esther L. Moss et al. GENES CHROMOSOMES & CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation